资讯

AstraZeneca (LSE:AZN) Anselamimab Shows Promise In AL Amyloidosis Despite Missing Main Endpoint
AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...